Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Journal subject
Affiliation country
Publication year range
1.
Molecules ; 20(8): 13536-49, 2015 Jul 23.
Article in English | MEDLINE | ID: mdl-26213908

ABSTRACT

The aim of the presented study was to examine in vitro the antibacterial activity of protocatechuic acid ethyl ester (ethyl 3,4-dihydroxybenzoate, EDHB) against Staphylococcus aureus clinical isolates alone and in the combination with four selected antibiotics. The EDHB antimicrobial activity was tested against twenty S. aureus strains isolated from the clinical samples, and three reference strains. The phenotypes and genotypes of resistance to methicillin for the tested strains were defined as well as the phenotypic resistance to macrolides, lincosamides and streptogramin B (MLSB). EDHB displayed diverse activity against examined S. aureus strains with the minimal inhibitory concentration (MIC) within the range from 64 to 1024 µg/mL. Addition of » MIC of EDHB into the Mueller-Hinton Agar (MHA) resulted in augmented antibacterial effect in the presence of clindamycin. In the case of cefoxitin no synergistic effect with EDHB was noted. For erythromycin and vancomycin the decrease of mean MICs in the presence of EDHB was observed but did not reach statistical significance. The results of the present study showed that in vitro EDHB possesses antibacterial activity against S. aureus clinical strains and triggers a synergistic antimicrobial effect with clindamycin and to the lesser extent with erythromycin and vancomycin.


Subject(s)
Anti-Bacterial Agents , Drug Resistance, Bacterial/drug effects , Hydroxybenzoates , Staphylococcus aureus/growth & development , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Humans , Hydroxybenzoates/chemistry , Hydroxybenzoates/pharmacology , Staphylococcus aureus/isolation & purification
2.
Regul Pept ; 156(1-3): 104-17, 2009 Aug 07.
Article in English | MEDLINE | ID: mdl-19328825

ABSTRACT

The human cathelicidin LL-37 is involved in innate immune responses, angiogenesis and wound healing. Functions in maintenance and re-establishment of intestinal barrier integrity have not been characterized yet. Following direct and indirect stimulation of human colonic HT-29 and Caco-2 cells with LL-37 the cellular viability, rate of apoptosis, proliferation and wound healing were determined. Expression of mucins and growth factors was quantified by real-time PCR and Western blotting. Direct application of LL-37 stimulated migration in Caco-2 cells expressing the proposed LL-37 receptor P2X7. Intestinal epithelial cell (IEC) proliferation was not altered. Indirectly, LL-37 significantly enhanced IEC migration via release of growth factors from subepithelial fibroblasts and IEC. Furthermore, LL-37 induced the expression of protective mucins in IEC and abated tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induced apoptosis in IEC. LL-37 induced signaling is mediated in part by the P2X7 receptor, the epidermal growth factor receptor and the p38 mitogen-activated protein kinase (MAPK). LL-37 contributes to maintenance and re-establishment of the intestinal barrier integrity via direct and indirect pathways. These features, in addition to its known antimicrobial properties, suggest an important role for this peptide in intestinal homeostasis.


Subject(s)
Cathelicidins/pharmacology , Epithelial Cells/cytology , Epithelial Cells/drug effects , Intestines/cytology , Peptide Fragments/pharmacology , Apoptosis/drug effects , Blotting, Western , Caco-2 Cells , Cell Line , Cell Proliferation/drug effects , Cell Survival/drug effects , HT29 Cells , Humans , Necrosis , Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL